Pharmacotherapy for Advanced Parkinson's Disease
Identifieur interne : 001B87 ( Main/Exploration ); précédent : 001B86; suivant : 001B88Pharmacotherapy for Advanced Parkinson's Disease
Auteurs : Mark Stacy [États-Unis]Source :
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [ 0277-0008 ] ; 2000-01.
Abstract
Medical management of Parkinson's disease consists of two strategies. A presynaptic strategy attempts to maintain physiologic synaptic concentrations of dopamine, usually by individualizing delivery of levodopa (or exogenous dopamine) by varying the rate of gastrointestinal absorption or blood‐brain barrier passage. A postsynaptic strategy bypasses degenerating nigrostriatal neurons by stimulating striatal neurons directly with dopamine agonists. With advancing disease, motor fluctuations appear, related to physiologic changes that narrow the window of levodopa concentration in which symptoms are under control. Then it becomes necessary to add dopamine agonists to therapy.
Url:
DOI: 10.1592/phco.20.2.8S.34630
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacotherapy for Advanced Parkinson's Disease</title><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D2C367BA2632C602E9F50F43B0E8DED4D67C8C83</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1592/phco.20.2.8S.34630</idno><idno type="url">https://api.istex.fr/document/D2C367BA2632C602E9F50F43B0E8DED4D67C8C83/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001035</idno><idno type="wicri:Area/Main/Curation">000E45</idno><idno type="wicri:Area/Main/Exploration">001B87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pharmacotherapy for Advanced Parkinson's Disease</title><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Arizona</region></placeName><wicri:cityArea>Muhammad Ali Parkinson Center, Barrow Neurological Institute, Phoenix</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</title><idno type="ISSN">0277-0008</idno><idno type="eISSN">1875-9114</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2000-01">2000-01</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">1P2</biblScope><biblScope unit="page" from="8S">8S</biblScope><biblScope unit="page" to="16S">16S</biblScope></imprint><idno type="ISSN">0277-0008</idno></series><idno type="istex">D2C367BA2632C602E9F50F43B0E8DED4D67C8C83</idno><idno type="DOI">10.1592/phco.20.2.8S.34630</idno><idno type="ArticleID">PHAR1634</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Medical management of Parkinson's disease consists of two strategies. A presynaptic strategy attempts to maintain physiologic synaptic concentrations of dopamine, usually by individualizing delivery of levodopa (or exogenous dopamine) by varying the rate of gastrointestinal absorption or blood‐brain barrier passage. A postsynaptic strategy bypasses degenerating nigrostriatal neurons by stimulating striatal neurons directly with dopamine agonists. With advancing disease, motor fluctuations appear, related to physiologic changes that narrow the window of levodopa concentration in which symptoms are under control. Then it becomes necessary to add dopamine agonists to therapy.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Arizona</li></region></list><tree><country name="États-Unis"><region name="Arizona"><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D2C367BA2632C602E9F50F43B0E8DED4D67C8C83
|texte= Pharmacotherapy for Advanced Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |